Research programme: long-acting eye disorder therapeutics - XL-protein GmbH/Easton Pharmaceutical
Latest Information Update: 09 Aug 2016
At a glance
- Originator Easton Pharmaceuticals; XL-protein GmbH
- Class Eye disorder therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Eye disorders